Robert Huddart

2 months ago | europeanurology.com | Daniele Raggi |Robert Huddart

Get full text accessLog in, subscribe or purchase for full access. References1. Lerner, S.P. ∙ Tangen, C. ∙ Svatek, R.S. ... Standard or extended lymphadenectomy for muscle-invasive bladder cancerN Engl J Med. 2024; 391:1206-12162. Zlotta, A.R. ∙ Ballas, L.K. ∙ Niemierko, A. ... Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysisLancet Oncol. 2023; 24:669-6813. Apolo, A.B. ∙ Ballman, K.V. ∙ Sonpavde, G. ...

Oct 28, 2024 | redjournal.org | Robert Huddart

⁎Radiation Oncology, HFR Fribourg, Villars-sur-Glâne, Switzerland†Faculty of Medicine, University of Geneva, Geneva, Switzerland‡Royal Marsden Hospital, London, United KingdomPublication History:Received August 9, 2024; Accepted September 2, 2024; Published online October 28, 2024DOI: 10.1016/j.ijrobp.2024.09.003Also available on ScienceDirectCopyright: © 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Feb 28, 2024 | onclive.com | Robert Huddart

February 28, 2024Robert Huddart, PhD, discusses the FDA approval of erdafitinib for patients with FGFR3-altered metastatic urothelial carcinoma.

Sep 30, 2023 | nature.com | Jakob Lauritsen |Di Jiang |Robert Huddart |Michal Chovanec |Christian D Fankhauser |Axel Heidenreich | +1 more

AbstractActive surveillance after orchiectomy is the preferred management in clinical stage I (CSI) germ-cell tumours (GCT) associated with a 15 to 30% relapse rate. In the IGCCCG Update database, we compared the outcomes of gonadal disseminated GCT relapsing from initial CSI to outcomes of patients with de novo metastatic GCT.